Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.

Discovery of novel SARS-CoV-2 main protease (M) inhibitors using a structure-based drug discovery strategy. Virtual screening employing covalent and noncovalent docking was performed to discover M inhibitors, which were subsequently evaluated in biochemical and cellular assays. 91 virtual hits were selected for biochemical assays, and four were confirmed as reversible inhibitors of SARS CoV-2 M with IC values of 0.4-3 μM. They were also shown to inhibit SARS-CoV-1 M and human cathepsin L. Molecular dynamics simulations indicated the stability of the M inhibitor complexes and the interaction of ligands at the subsites. This approach led to the discovery of novel thiosemicarbazones as potent SARS-CoV-2 M inhibitors.